Trials / Terminated
TerminatedNCT04138199
A Study to Assess Effectiveness and Safety of Fixed Dose Combination of Lopinavir/Ritonavir (LPV/r) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Patients After Switching From Kaletra in the Routine Clinical Settings of Russian Federation
Multi-Center Observational Study to Assess Effectiveness and Safety of Fixed Dose Combination of Generic Product of Lopinavir/Ritonavir in HIV-1 Infected Patients After Switching From Kaletra® (Lopinavir/Ritonavir) for Administrative Reasons in the Routine Clinical Settings of Russian Federation (COPI)
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 239 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a mixed prospective-retrospective, multi-center observational study to assess the virologic effectiveness of generic product of Lopinavir/Ritonavir (LPV/r) after switching from Kaletra in the routine clinical settings of Russian Federation.
Conditions
Timeline
- Start date
- 2019-11-01
- Primary completion
- 2020-07-08
- Completion
- 2020-07-08
- First posted
- 2019-10-24
- Last updated
- 2021-07-06
Locations
10 sites across 1 country: Russia
Source: ClinicalTrials.gov record NCT04138199. Inclusion in this directory is not an endorsement.